Nyxoah SA (NYXH), a Belgian medical technology company developing the Genio hypoglossal nerve-stimulation system for obstructive sleep apnea (OSA), is a stock, not an ETF. The central target of $3.40 is the arithmetic mean of five recent, attributable analyst price targets collected from firms that disclose the analyst, firm, target, and date.
The five targets are: Stifel (Hold, $1.50, November 2026), Cantor Fitzgerald (Buy, $3.00, October 2026), Robert W. Baird (Neutral, $2.31, August 2026), Oppenheimer (Buy, $4.00, August 2026), and Piper Sandler (Buy, $6.00, August 2026). The mean is approximately $3.36, rounded to $3.40, with a range of $1.50 to $6.00. This wide dispersion — a fourfold gap between the low and high — reflects fundamentally different views on how quickly Genio can scale in the U.S. Bullish analysts emphasize commercial momentum and label expansion; cautious analysts emphasize execution risk, valuation, and dilution.
With the stock trading near $0.90, reaching the $3.40 average analyst price target implies a rise of roughly 280%, a very large move for a stock that has fallen from a 52-week high near $5.92 to a 52-week low near $0.80. The stock has also generated positive momentum recently, with U.S. revenue up 29% sequentially in the third quarter of 2026.
The path would depend on sustained U.S. adoption of Genio, which received FDA approval in August 2025, and on a successful expansion of its indication to Complete Concentric Collapse (CCC) patients. Nyxoah reported that its ACCCESS pivotal study met its efficacy and safety endpoints in CCC patients and that it has submitted a premarket approval (PMA) supplement to the FDA. A favorable regulatory outcome could meaningfully expand the addressable market, but commercialization remains early-stage.
The most important supporting factors are commercial and clinical. Nyxoah has been expanding its U.S. footprint, training additional surgeons and activating new high-volume accounts each quarter. Genio's differentiated design — leadless and battery-free — positions it as an alternative in hypoglossal nerve stimulation, a segment historically dominated by a single large competitor. The ACCCESS data and the pending CCC indication could open a patient group where competing therapies have been contraindicated. With roughly €77 million in cash and financial assets at the end of the third quarter, the company has near-term liquidity to fund the ramp.
The principal obstacles are financial. Nyxoah cut its full-year 2026 revenue guidance to €33–35 million from €36–40 million, signaling that the U.S. ramp is unfolding more slowly than earlier expectations. The company remains deeply unprofitable, with negative EPS (earnings per share) and ongoing cash burn. A $95 million underwritten public offering in 2026 provided capital but diluted existing shareholders and weighed on the stock. Competition in sleep-apnea treatment, reimbursement uncertainty, and the inherent difficulty of scaling a new implantable device are additional headwinds. These factors help explain why several analysts have repeatedly lowered their targets over the past year.
The stock's technical structure reflects a sharp drawdown. The 52-week range of roughly $0.80 to $5.92 means the current price sits near the low end of that band. The $0.80 area represents a meaningful support level, while any recovery would first need to reclaim levels near and above $1.00–$1.50 before the analyst range of $1.50 to $6.00 becomes relevant. The $1.50 low end of the analyst range itself functions as a notable near-term reference point.
Analyst price targets typically reflect a research horizon of about 12 months, though individual firms may differ. Investors should monitor quarterly U.S. revenue growth, surgeon and account additions, the pace of cash burn, any update on the FDA review of the CCC PMA supplement, and analyst revisions. Because several targets were issued in August 2026 and the stock has declined sharply since, further target adjustments are possible as analysts incorporate the latest commercialization data and any new financing activity.
For traders looking to track changing conditions across thousands of securities, Tickeron's AI Daily Buy/Sell Signals offer a systematic way to follow market behavior. The system uses artificial intelligence to continuously monitor stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. It is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual review allows. While no signal replaces independent research, tools like this can complement a broader decision-making process.
The question of whether Nyxoah (NYXH) can reach $3.40 is, in effect, a question about whether the company can re-establish investor confidence after a steep decline. The central target reflects a broad analyst range of $1.50 to $6.00, with the arithmetic mean of five verified targets landing near $3.40. From roughly $0.90, that requires a very large move of about 280%. The bull case rests on Genio's U.S. launch and a potential label expansion; the bear case rests on slowing-than-expected adoption, a guidance cut, dilution, and cash burn. Neither outcome is guaranteed, and the wide analyst dispersion underscores the uncertainty. Investors should track quarterly execution, regulatory milestones, and analyst revisions rather than treat any single price target as a forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, NYXH has been loosely correlated with NUWE. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if NYXH jumps, then NUWE could also see price increases.
| Ticker / NAME | Correlation To NYXH | 1D Price Change % | ||
|---|---|---|---|---|
| NYXH | 100% | +0.66% | ||
| NUWE - NYXH | 35% Loosely correlated | +6.07% | ||
| TXG - NYXH | 27% Poorly correlated | -3.31% | ||
| CLPT - NYXH | 26% Poorly correlated | -4.36% | ||
| RGEN - NYXH | 26% Poorly correlated | -2.77% | ||
| PROF - NYXH | 25% Poorly correlated | +4.63% | ||
More | ||||
| Ticker / NAME | Correlation To NYXH | 1D Price Change % |
|---|---|---|
| NYXH | 100% | +0.66% |
| Health Services category (239 stocks) | 2% Poorly correlated | +0.37% |
| Medical/Nursing Services category (138 stocks) | 2% Poorly correlated | +0.85% |